Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
RB Oliveira, ALE Cancela, FG Graciolli… - Clinical Journal of the …, 2010 - journals.lww.com
Background and objectives: Levels of parathyroid hormone (PTH) and the phosphaturic
hormone FGF23, a fibroblast growth factor (FGF) family member, increase early in chronic
kidney disease (CKD) before the occurrence of hyperphosphatemia. This short-term 6-wk
dose titration study evaluated the effect of two phosphate binders on PTH and FGF23 levels
in patients with CKD stages 3 to 4.
hormone FGF23, a fibroblast growth factor (FGF) family member, increase early in chronic
kidney disease (CKD) before the occurrence of hyperphosphatemia. This short-term 6-wk
dose titration study evaluated the effect of two phosphate binders on PTH and FGF23 levels
in patients with CKD stages 3 to 4.